Mink Therapeutics (INKT) Stock News

MiNK Therapeutics (NASDAQ: INKT) announced a publication in Frontiers in Immunology highlighting their innovative iNKT cell therapy platform. The article focuses on their lead program agenT-797, an unmodified allogeneic iNKT therapy, which has shown promising results in solid tumors without requiring lymphodepletion or genetic modification.

The company reported a notable case where a patient with metastatic testicular cancer achieved complete remission using agenT-797 combined with anti-PD-1 therapy, remaining disease-free for over two years. Additionally, in a Phase 2 trial for second-line gastric cancer, the therapy demonstrated enhanced tumor infiltration and durable disease control.

MiNK is also advancing MiNK-215, an IL-15-armored, FAP-targeting CAR-iNKT cell therapy designed to overcome stromal barriers in resistant tumors.

MiNK Therapeutics (NASDAQ: INKT) announced a groundbreaking publication in Nature's Oncogene detailing a complete remission case in metastatic testicular cancer using their agenT-797 allogeneic iNKT cell therapy. The patient, who had previously failed multiple treatments including platinum-based chemotherapy and immunotherapies, achieved complete remission lasting over two years after a single infusion of agenT-797 with nivolumab.

The therapy demonstrated remarkable safety with no cytokine release syndrome or graft-versus-host disease. Additionally, MiNK presented promising Phase 2 trial data in gastric cancer showing extended survival beyond 12 months in several patients, with a separate case reporting 42% tumor reduction and nine months progression-free survival.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, has announced its Annual Shareholders Meeting will be held virtually on June 18, 2025, at 9:30 a.m. ET. Shareholders can participate by visiting www.virtualshareholdermeeting.com/INKT2025 using their 16-digit control number from proxy materials. Registration opens at 9:15 a.m. ET. Guests can access the meeting in listen-only mode without a control number. The meeting will be available via webcast on the company's investor relations website and the virtual shareholder meeting platform.

MiNK Therapeutics (NASDAQ: INKT) has received a prestigious NIAID grant to advance its allogeneic iNKT cell therapy platform for preventing and treating graft-versus-host disease in stem cell transplant patients. The company is collaborating with the University of Wisconsin to develop this innovative treatment. The research targets a significant unmet need, as nearly 50% of patients undergoing allogeneic stem cell transplants are at risk for GvHD, a severe immune complication with high mortality rates. The non-dilutive funding validates MiNK's iNKT platform, which uniquely regulates immune responses, promotes tissue repair, and suppresses inflammatory pathways. The collaboration combines MiNK's advanced iNKT manufacturing capabilities with the University of Wisconsin's expertise in transplant immunology.

MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2025 financial results and clinical progress. The company achieved a significant breakthrough with a complete remission in testicular cancer using a single infusion of agenT-797. Clinical trials are advancing, including an active Phase 2 trial in gastric cancer at Memorial Sloan Kettering. The company presented promising data showing agenT-797's effectiveness in PD-1-resistant gastroesophageal cancers. MiNK is pursuing strategic partnerships in oncology, immunology, and engineered cell therapies. Financially, Q1 2025 ended with $3.2 million cash, reduced cash burn to $1.3 million (vs $2.5M in Q1 2024), and a net loss of $2.8 million ($0.70 per share). The company expects NIAID funding for its GvHD program by June 2025.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its first quarter 2025 financial results release for May 15, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update.

Investors can access the conference call via dial-in numbers 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 9822477. A live webcast and replay will be available through the company's investor relations website.

MiNK Therapeutics (NASDAQ: INKT) reported its Q4 and full year 2024 financial results, highlighting progress in developing allogeneic iNKT cell therapies. The company's lead candidate, AgenT-797, showed promising results in cancer treatment and inflammatory lung conditions, with an 80% survival rate in VV ECMO patients versus 10% in hospital controls.

Key developments include a Phase 2 trial in advanced gastric cancer, next-generation PRAME-TCR iNKTs development, and MiNK-215 showing anti-tumor activity in colorectal cancer models. The company secured a research collaboration with Autonomous Therapeutics and raised $5.8M in private financing.

Financial results show a year-end cash balance of $4.6M, reduced cash burn with operations using $9.6M in 2024 compared to $15.8M in 2023. Net loss improved to $10.8M ($2.86 per share) in 2024 from $22.5M ($6.54 per share) in 2023.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its fourth quarter and full year 2024 financial results release for March 18th, 2025, before market opening.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring a corporate update and discussion of financial results. Investors can access the call via phone at 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 8023784, or through the company's investor relations website.

MiNK Therapeutics (NASDAQ: INKT) presented new translational data from its ongoing Phase 2 study of allo-iNKTs (agenT-797) at the AACR IO Annual Meeting. The study evaluates agenT-797 in combination with botensilimab and balstilimab (BOT/BAL) in patients with refractory gastroesophageal cancer.

The data demonstrated synergy between allo-iNKT cells, checkpoint inhibitors, and chemotherapy, showing robust immune reactivation in unresponsive tumors. Key findings include significant increases in interferon-gamma levels and enhanced tumor infiltration by T cells and antigen-presenting cells. The study revealed that optimal results were achieved when agenT-797 was administered concurrently with checkpoint inhibitors before chemotherapy.

MiNK's allogeneic manufacturing process can generate billions of donor-derived iNKT cells in a single run, producing thousands of doses for global distribution, potentially reducing costs and improving patient access.